person · Reporting owner
Longsworth Todd Christopher
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | General Counsel | March 08, 2022 | March 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date March 08, 2022 · Filed March 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 62,462 |
Reported balance
After 2022-03-08 transaction · row 1
1 source rowRow 1 · 2022-03-08 · Sale · Disposed 2,339 · Balance 62,462 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 56,874 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · derivative · entry 23 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,799 Underlying: Ordinary Shares · 56,874 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F18 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 11,632 | $0.00 Strike: $6.72 | $0.00 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · derivative · entry 22 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,632 shares Expires 2022-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F18 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 59,520 | $0.00 Strike: $6.72 | $0.00 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · derivative · entry 21 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 59,520 shares Expires 2022-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F18 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,200 | $89.86 | $107,828.40 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 20 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,900 F17 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 1,200 shares in multiple trades at prices ranging from $89.54 to $90.11. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,900 | $88.86 | $257,702.70 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 19 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,100 F16 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 2,900 shares in multiple trades at prices ranging from $88.53 to $89.36. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 14,888 | $88.18 | $1,312,794.06 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 18 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 F15 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 14,888 shares in multiple trades at prices ranging from $87.52 to $88.51. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 11,426 | $86.86 | $992,439.51 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 17 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,888 F14 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 11,426 shares in multiple trades at prices ranging from $86.40 to $87.24. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 30,414 | $21.15 | $643,256.10 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 16 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,031 | $89.87 | $362,261.94 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 15 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,900 F13 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 4,031 shares in multiple trades at prices ranging from $89.54 to $90.32. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,869 | $88.97 | $700,128.54 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 14 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,931 F12 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 7,869 shares in multiple trades at prices ranging from $88.53 to $89.50. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 24,083 | $88.22 | $2,124,481.85 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 13 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,800 F11 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 24,083 shares in multiple trades at prices ranging from $87.52 to $88.51. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 20,891 | $86.95 | $1,816,556.01 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 12 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,883 F10 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 20,891 shares in multiple trades at prices ranging from $86.40 to $87.27. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 56,874 | $7.15 | $406,649.10 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 11 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 400 | $89.97 | $35,987.60 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 10 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,900 F9 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 400 shares in multiple trades at prices ranging from $89.79 to $90.18. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 929 | $88.94 | $82,622.47 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 9 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,300 F8 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 929 shares in multiple trades at prices ranging from $88.55 to $89.41. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,065 | $88.19 | $534,896.61 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 8 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,229 F7 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 6,065 shares in multiple trades at prices ranging from $87.55 to $88.54. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,238 | $86.88 | $368,205.92 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 7 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,294 F6 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 4,238 shares in multiple trades at prices ranging from $86.49 to $87.25. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 11,632 | $6.72 | $78,167.04 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 6 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,300 | $89.90 | $206,758.50 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 5 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,900 F5 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 2,300 shares in multiple trades at prices ranging from $89.54 to $90.26. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,616 | $88.82 | $587,619.89 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 4 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,200 F4 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 6,616 shares in multiple trades at prices ranging from $88.52 to $89.44. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 28,340 | $88.17 | $2,498,766.14 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 3 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,816 F3 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 28,340 shares in multiple trades at prices ranging from $87.52 to $88.51. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 22,264 | $86.85 | $1,933,539.34 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,156 F2 · price: On September 3, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth, Mr. Longsworth sold 22,264 shares in multiple trades at prices ranging from $86.37 to $87.24. The price reported above reflects the weighted average sale price. Mr. Longsworth hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 59,520 | $6.72 | $399,974.40 |
DisclosureSEC source: 0001209191-19-048481 · doc4.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 16:25 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 696 | $27.81 | $19,357.15 |
DisclosureSEC source: 0001209191-19-041559 · doc4.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,900 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2019 through June 30, 2019. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2019. Read SEC document |
| May 08, 2019 Filed May 10, 2019 16:15 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 20,000 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001209191-19-028884 · doc4.xml · derivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires 2029-05-08 F2 · derivative.exercise_date: Options to buy 20,000 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $71.34 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Longsworth has been continuously employed by the Company through May 8, 2022. Read SEC document |
| May 08, 2019 Filed May 10, 2019 16:15 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 29,320 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001209191-19-028884 · doc4.xml · derivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,320 Underlying: Ordinary Shares · 29,320 shares Expires 2029-05-08 F1 · derivative.exercise_date: Options to buy 29,320 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $59.45 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Longsworth has been continuously employed by the Company through May 8, 2022. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 16:33 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 29,969 | $0.00 Strike: $47.04 | $0.00 |
DisclosureSEC source: 0001209191-19-021332 · doc4.xml · derivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,969 Underlying: Ordinary Shares · 29,969 shares Expires 2029-03-21 F2 · derivative.exercise_date: Options to buy 29,969 ordinary shares will vest and become exercisable in equal installments on each of March 5, 2020, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 22, 2019 Filed Mar 26, 2019 16:33 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Share Units | 16,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021332 · doc4.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,204 F1 · shares: Represents restricted share units that are scheduled to vest on March 5, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 16:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,368 | $53.68 | $127,114.24 |
DisclosureSEC source: 0001209191-19-014989 · doc4.xml · nonDerivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,835 F1 · price: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 5,556 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-014989 · doc4.xml · derivative · entry 3 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,111 Underlying: Ordinary Shares · 5,556 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 16:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,556 | $52.90 | $293,912.40 |
DisclosureSEC source: 0001209191-19-014989 · doc4.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 17:54 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 9,325 | $53.63 | $500,081.10 |
DisclosureSEC source: 0001209191-19-013678 · doc4.xml · nonDerivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,647 F1 · price: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 17:54 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 21,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-013678 · doc4.xml · derivative · entry 3 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,666 Underlying: Ordinary Shares · 21,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 17:54 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 21,667 | $53.38 | $1,156,584.46 |
DisclosureSEC source: 0001209191-19-013678 · doc4.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2019 Filed Jan 28, 2019 16:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 11,874 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001209191-19-005514 · doc4.xml · derivative · entry 6 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,673 Underlying: Ordinary Shares · 11,874 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested and exercisable as of the date hereof. Read SEC document |
| January 25, 2019 Filed Jan 28, 2019 16:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 11,874 | $50.15 | $595,481.10 |
DisclosureSEC source: 0001209191-19-005514 · doc4.xml · nonDerivative · entry 4 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,305 F2 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth. Read SEC document |
| January 25, 2019 Filed Jan 28, 2019 16:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 11,874 | $7.15 | $84,899.10 |
DisclosureSEC source: 0001209191-19-005514 · doc4.xml · nonDerivative · entry 3 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 16:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 15,000 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001209191-19-005514 · doc4.xml · derivative · entry 5 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,547 Underlying: Ordinary Shares · 15,000 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested and exercisable as of the date hereof. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 16:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 15,000 | $48.15 | $722,250.00 |
DisclosureSEC source: 0001209191-19-005514 · doc4.xml · nonDerivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,305 F2 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 16:15 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 15,000 | $7.15 | $107,250.00 |
DisclosureSEC source: 0001209191-19-005514 · doc4.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 16:12 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 15,000 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001209191-19-004546 · doc4.xml · derivative · entry 3 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,547 Underlying: Ordinary Shares · 15,000 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested and exercisable as of the date hereof. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 16:12 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 15,000 | $45.15 | $677,250.00 |
DisclosureSEC source: 0001209191-19-004546 · doc4.xml · nonDerivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,305 F2 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 16:12 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 15,000 | $7.15 | $107,250.00 |
DisclosureSEC source: 0001209191-19-004546 · doc4.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 16:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 15,000 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001209191-19-003417 · doc4.xml · derivative · entry 3 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,547 Underlying: Ordinary Shares · 15,000 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested and exercisable as of the date hereof. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 16:21 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 15,000 | $40.15 | $602,250.00 |
DisclosureSEC source: 0001209191-19-003417 · doc4.xml · nonDerivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,305 F2 · price: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 16:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 15,000 | $7.15 | $107,250.00 |
DisclosureSEC source: 0001209191-19-003417 · doc4.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares were acquired pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth. Read SEC document |
| July 06, 2018 Filed Jul 10, 2018 16:12 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 1,231 | $17.26 | $21,240.91 |
DisclosureSEC source: 0001209191-18-042140 · doc4.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,305 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2018 through June 30, 2018. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 2, 2018. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 16:22 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Unit · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-015016 · doc4.xml · derivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Ordinary Shares · 16,667 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share. F3 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 27, 2019, 2020 and 2021, subject to the reporting person's continued employment through such dates. F3 · derivative.expiration_date: One-third of these restricted stock units are scheduled to vest on each of February 27, 2019, 2020 and 2021, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 16:22 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 121,655 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001209191-18-015016 · doc4.xml · derivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,655 Underlying: Ordinary Shares · 121,655 shares Expires 2028-02-27 F1 · derivative.exercise_date: Options to buy 121,655 ordinary shares will vest and become exercisable in equal installments on each of February 27, 2019, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 17:14 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,591 | $19.83 | $130,686.35 |
DisclosureSEC source: 0001209191-18-013433 · doc4.xml · nonDerivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,074 F1 · price: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.